NCT00073944View on ClinicalTrials.gov

BCX-1777 in Treating Patients With Refractory Cancer

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

April 30, 2003

Primary Completion Date

January 31, 2005

Conditions
Cancer
Interventions
DRUG

forodesine hydrochloride

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY

NCT00073944 - BCX-1777 in Treating Patients With Refractory Cancer | Biotech Hunter | Biotech Hunter